228401-16-9

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 3279-07-0 4-tert-butyl-2-nitrophenol 
• 421-83-0 trifluoromethane sulfonyl chloride 

Downstream Products

• 855304-77-7 4-tert-butyl-1-methylsulfanyl-2-nitro-benzene 
• 3279-07-0 4-tert-butyl-2-nitrophenol 
• 1147530-71-9 (4-tert-butyl-2-nitrophenylethynyl)trimethylsilane 
• 340825-36-7 4-tert-butyl-2-nitro-N-[2-(morpholin-4-yl)ethyl]aniline 
• 340825-34-5 3-bromo-5-tert-butyl-2-[2-(morpholin-4-yl)ethylamino]aniline 

Relevant academic research and scientific papers

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITORS OF HSP90

The invention relates to the use of benzoimidazolone compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising b

1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION

Disclosed are compounds of formula (I), where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines and are thus useful for treating cytokine mediated diseases. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Disclosed are compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclos

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Compounds useful as anti-inflammatory agents

Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.